The 15 days that decide whether you get a warning letter
An FDA Form 483 “notifies the company’s management of objectionable conditions” at the end of an inspection. It “does not constitute a final Agency determination,” and FDA encourages companies “to respond to the FDA Form 483 in writing with their corrective action plan” (FDA).
Timing matters. Since 2009, “FDA will generally allow firms 15 business days to provide a response to FDA 483 observations.” A response received in time is reviewed in detail before FDA decides on a warning letter. A late one usually is not: FDA “will not ordinarily delay the issuance of a warning letter” (Federal Register).
For what a Form 483 is and the observations FDA cites most, see FDA Form 483 Explained: What It Means, Top Observations and How to Respond.
What FDA cites most
| Area | FY2025 top citations (system-generated 483s) |
|---|---|
| Devices (2,660 citations) | § 820.100(a) CAPA procedures: 279; § 820.198(a) complaints: 211; § 820.50 purchasing: 115; § 820.90(a) nonconforming product: 95; § 820.75(a) process validation: 93 |
| Drugs (2,837 citations) | § 211.22(d) quality unit procedures: 243; § 211.192 investigations: 164; § 211.100(a) written procedures: 162 |
Source: GMP Insiders analysis of FDA data. FDA notes its spreadsheets cover only system-generated 483s and are “not a comprehensive listing of all inspectional observations” (FDA).
For devices, the rulebook changed on February 2, 2026. In the first ~100 QMSR inspections, the top topics were risk management, outsourcing and purchasing, complaint handling, UDI and corrective action (RAPS).
2026 trends that affect your response
- New draft guidance for drug sites. In March 2026, FDA issued draft guidance on “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection” (Federal Register). It is a draft and covers drug CGMP inspections only. It recommends “one organized written response within 15 business days, rather than piecemeal submissions,” signed “by a member of executive management” (Venable), and cites past responses that failed “to address the root cause.”
- More unannounced foreign inspections. In May 2025, FDA said it would “expand the use of unannounced inspections at foreign manufacturing facilities” (FDA).
- AI-assisted targeting. FDA says its AI tool Elsa is used to “identify high-priority inspection targets” (FDA).
The FDA 483 response checklist
The structure below follows the elements law firms highlight from FDA’s 2026 draft guidance (Arnold & Porter; RAPS). It is written for drug sites but works as a sound structure for device firms too.
Day 0–2: Organize
- Calendar the 15-business-day deadline from the inspection close
- Assign an owner and a cross-functional team per observation
- Assess immediate patient and product risk; decide on any holds or field actions
Day 2–10: Investigate
- Investigate each observation to root cause, not just the specific example cited
- Assess whether other products, lines or sites are affected (systemic scope)
- Avoid “human error” as a final root cause without supporting evidence
- Define corrections, corrective actions and effectiveness checks with dates
Day 10–15: Write and submit
- One organized response, signed by executive management
- Table of contents and a copy of the 483
- Executive summary table: observation, root cause, actions, owner, target date, status
- Objective evidence attached for completed actions (revised SOPs, training records, data)
- Realistic timelines for open actions and a commitment to interim updates
- Correspondence in English, with translations accompanied by originals
After submission
- Send interim updates as actions close
- Verify effectiveness and keep evidence ready for the next inspection
Common mistakes
| Mistake | Why it hurts | Better approach |
|---|---|---|
| Fixing only the cited example | FDA reads it as a missed systemic issue | Show the scope assessment across products and sites |
| ”Retrained the operator” as the only action | Training rarely addresses root cause | Show the process or system change, then training |
| Promises without dates or evidence | Cannot be verified | Dated commitments plus attached evidence |
| Late or piecemeal responses | FDA may not review before deciding on a warning letter | One complete response within 15 business days |
Get your evidence straight before you write
A strong 483 response depends on finding every related procedure, record and prior investigation fast, then showing exactly how each was fixed. AI document assessment can map your SOPs and records against the cited requirement, flag related gaps the investigator did not list, and cite the passage behind every finding.
Run a sample regulatory document assessment on the SOPs behind one observation. AskDona shows the evidence; your team decides.
FAQ
Do I have to respond to a Form 483? Responding is voluntary, but FDA encourages a written response with a corrective action plan (FDA).
How long do I have? Generally 15 business days for FDA to consider the response before deciding on a warning letter (Federal Register).
Is a 483 a finding of violation? No. It “does not constitute a final Agency determination” (FDA).
Does the 2026 draft guidance apply to device makers? No. It covers drug CGMP inspections and is still a draft (Venable).
References
All pages opened and checked by October 9, 2026.
| Source | Type | Date | Used for |
|---|---|---|---|
| FDA: Form 483 FAQ | Regulator | 2020 | What a 483 is |
| Federal Register: Review of Post-Inspection Responses | Regulator | Aug 11, 2009 | 15 business days |
| Federal Register: Draft 483 response guidance | Regulator | Mar 9, 2026 | Draft guidance, root cause |
| Arnold & Porter: FDA guidance on 483 responses | Law firm | Mar 12, 2026 | Recommended contents |
| Venable: Roadmap for responding | Law firm | Jun 12, 2026 | One response, executive signature |
| RAPS: FDA drafts 483 response guidance | Trade press | Mar 6, 2026 | Table of contents, language |
| GMP Insiders: FY2025 observations | Industry analysis | Jan 5, 2026 | Top citations |
| FDA: Inspection observations datasets | Regulator data | Dec 2025 | Dataset caveat |
| RAPS: Top QMSR observations | Trade press | May 14, 2026 | QMSR topics |
| FDA: Unannounced foreign inspections | Regulator | May 6, 2025 | Foreign inspections |
| FDA: Elsa launch | Regulator | Jun 2, 2025 | AI targeting |